AU7298398A - Enhanced effects for hapten conjugated therapeutics - Google Patents
Enhanced effects for hapten conjugated therapeuticsInfo
- Publication number
- AU7298398A AU7298398A AU72983/98A AU7298398A AU7298398A AU 7298398 A AU7298398 A AU 7298398A AU 72983/98 A AU72983/98 A AU 72983/98A AU 7298398 A AU7298398 A AU 7298398A AU 7298398 A AU7298398 A AU 7298398A
- Authority
- AU
- Australia
- Prior art keywords
- enhanced effects
- hapten conjugated
- therapeutics
- conjugated therapeutics
- hapten
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75267196A | 1996-11-19 | 1996-11-19 | |
| US08/752671 | 1996-11-19 | ||
| PCT/US1997/018475 WO1998022141A2 (fr) | 1996-11-19 | 1997-11-06 | Effets renforces pour therapeutique associee a l'haptene |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU7298398A true AU7298398A (en) | 1998-06-10 |
Family
ID=25027301
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU72983/98A Abandoned AU7298398A (en) | 1996-11-19 | 1997-11-06 | Enhanced effects for hapten conjugated therapeutics |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP1027073A2 (fr) |
| AU (1) | AU7298398A (fr) |
| WO (1) | WO1998022141A2 (fr) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000022112A1 (fr) | 1998-10-13 | 2000-04-20 | The University Of Georgia Research Foundation, Inc. | Peptides bioactifs stabilises, procedes d'identification, synthese et utilisation |
| US20030190740A1 (en) | 1998-10-13 | 2003-10-09 | The University Of Georgia Research Foundation, Inc | Stabilized bioactive peptides and methods of identification, synthesis, and use |
| WO2001032207A1 (fr) * | 1998-10-30 | 2001-05-10 | United States Army Medical Research And Materiel Command | Procede permettant d'appliquer une immunotherapie active/passive |
| JP2003518075A (ja) * | 1999-12-24 | 2003-06-03 | ジェネンテック・インコーポレーテッド | 生理活性化合物の消失半減期延長のための方法及び組成物 |
| EP1757311B1 (fr) * | 1999-12-24 | 2009-02-11 | Genentech, Inc. | Méthodes et compositions pour la prolongation de la demi-période d'élimination de composés bioactifs |
| CN100560131C (zh) | 2001-10-22 | 2009-11-18 | 斯克里普斯研究学院 | 抗体靶向化合物 |
| EP1888640B1 (fr) | 2005-05-18 | 2012-03-14 | Ablynx N.V. | Nanocorps ameliores utilises contre le facteur-alpha de necrose tumorale |
| WO2008074840A2 (fr) | 2006-12-19 | 2008-06-26 | Ablynx N.V. | Séquences d'acides aminés dirigées contre une métalloprotéinase de la famille adam et polypeptides les comprenant à des fins de traitement de maladies et troubles liés à adam |
| EP2557090A3 (fr) | 2006-12-19 | 2013-05-29 | Ablynx N.V. | Séquences d'acides aminés dirigées contre les GPCR et polypeptides les comprenant pour le traitement de maladies et de troubles liés au GPCR |
| WO2009124931A2 (fr) | 2008-04-07 | 2009-10-15 | Ablynx Nv | Séquences d'acides aminés dirigées contre les voies notch et leurs utilisations |
| CA2731617A1 (fr) | 2008-07-22 | 2010-01-28 | Maria Joao Saraiva | Sequences d'acides amines dirigees contre des recepteurs de desactiveurs multicibles et polypeptides |
| US8748581B2 (en) | 2009-04-10 | 2014-06-10 | Ablynx N.V. | Anti-IL-6R polypeptides and pharmaceutical compositions thereof |
| SG176095A1 (en) | 2009-06-05 | 2011-12-29 | Ablynx Nv | Monovalent, bivalent and trivalent anti human respiratory syncytial virus (hrsv) nanobody constructs for the prevention and/or treatment of respiratory tract infections |
| EP2507262A1 (fr) | 2009-11-30 | 2012-10-10 | Ablynx N.V. | Séquences d'acides aminés améliorées dirigées contre le virus syncytial respiratoire humain (hrsv) et polypeptides comprenant celles-ci pour la prévention et/ou le traitement d'infections du tractus respiratoire |
| EP2513145B1 (fr) | 2009-12-14 | 2018-01-24 | Ablynx N.V. | Domaines variables uniques de liaison anti-ox40l, construits et application therapeutique |
| WO2011083140A1 (fr) | 2010-01-08 | 2011-07-14 | Ablynx Nv | Domaines variables simples d'immunoglobuline dirigés contre le cxcr4 doués d'une meilleure activité thérapeutique et produits de recombinaison les comprenant |
| US9120855B2 (en) | 2010-02-10 | 2015-09-01 | Novartis Ag | Biologic compounds directed against death receptor 5 |
| EP3546483A1 (fr) | 2010-05-20 | 2019-10-02 | Ablynx N.V. | Matériaux biologiques associés à her3 |
| EP2638068B1 (fr) | 2010-11-08 | 2018-12-26 | Novartis AG | Polypeptides se liant aux récepteurs de cxcr2 |
| UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
| JP2014525736A (ja) | 2011-06-23 | 2014-10-02 | アブリンクス エン．ヴェー． | ＩｇＥに対する免疫グロブリン単一可変ドメイン |
| US9328174B2 (en) | 2012-05-09 | 2016-05-03 | Novartis Ag | Chemokine receptor binding polypeptides |
| WO2014087010A1 (fr) | 2012-12-07 | 2014-06-12 | Ablynx N.V. | Polypeptides améliorés dirigés contre ige |
| NL2013661B1 (en) | 2014-10-21 | 2016-10-05 | Ablynx Nv | KV1.3 Binding immunoglobulins. |
| WO2018014260A1 (fr) | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Protéines de liaison antigènes multi-spécifiques et leurs procédés d'utilisation |
| WO2018068201A1 (fr) | 2016-10-11 | 2018-04-19 | Nanjing Legend Biotech Co., Ltd. | Anticorps à domaine unique et ses variants contre ctla-4 |
| CA3043515A1 (fr) | 2016-11-16 | 2018-05-24 | Ablynx Nv | Polypeptides de recrutement de lymphocytes t capables de se lier a cd123 et tcr alpha/beta |
| EP3630818A1 (fr) | 2017-06-02 | 2020-04-08 | Ablynx NV | Immunoglobulines liant l'aggrécane |
| CA3082280A1 (fr) | 2017-12-28 | 2019-07-04 | Nanjing Legend Biotech Co., Ltd. | Anticorps a domaine unique et leurs variants diriges contre tigit |
| EP3740507A4 (fr) | 2018-01-15 | 2022-08-24 | Nanjing Legend Biotech Co., Ltd. | Anticorps à domaine unique et des variants de celui-ci dirigés contre pd-1 |
| WO2019185040A1 (fr) | 2018-03-30 | 2019-10-03 | Nanjing Legend Biotech Co., Ltd. | Anticorps à domaine unique contre lag-3 et leurs utilisations |
| IL305301A (en) | 2021-02-19 | 2023-10-01 | Us Health | Single domain antibodies neutralizing SARS CoV-2 |
| WO2024083843A1 (fr) | 2022-10-18 | 2024-04-25 | Confo Therapeutics N.V. | Séquences d'acides aminés dirigées contre le récepteur de la mélanocortine 4 et polypeptides les comprenant pour le traitement de maladies et de troubles liés à mc4r |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5888512A (en) * | 1987-01-30 | 1999-03-30 | Board Of Trustees Of The Leland Stanford Junior University | Lymphocyte activity regulation by HLA peptides |
| DE4238416A1 (de) * | 1992-11-13 | 1994-05-19 | Max Planck Gesellschaft | Bestimmung von Peptidmotiven auf MHC-Molekülen |
| WO1995034321A1 (fr) * | 1994-06-16 | 1995-12-21 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation immunitaire a l'aide de fragments de chaine alpha de classe ii |
| US5753625A (en) * | 1995-05-12 | 1998-05-19 | Sangstat Medical Corporation | Treatment for inhibiting the progression of autoimmune disease |
| AU1823697A (en) * | 1996-01-02 | 1997-07-28 | Board Of Trustees Of The Leland Stanford Junior University | Interaction of hla proteins with members of the hsp70 family of proteins |
| ATE255910T1 (de) * | 1996-04-10 | 2003-12-15 | Sangstat Medical Corp | Zellmodulierende konjugate aus elementen aus spezifischen bindungspaaren |
-
1997
- 1997-11-06 AU AU72983/98A patent/AU7298398A/en not_active Abandoned
- 1997-11-06 EP EP97949336A patent/EP1027073A2/fr not_active Withdrawn
- 1997-11-06 WO PCT/US1997/018475 patent/WO1998022141A2/fr not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO1998022141A3 (fr) | 1999-01-07 |
| WO1998022141A2 (fr) | 1998-05-28 |
| EP1027073A2 (fr) | 2000-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU7298398A (en) | Enhanced effects for hapten conjugated therapeutics | |
| TJ328B (en) | Interferron conjugates | |
| AU7616396A (en) | Substation | |
| AU4032397A (en) | Imidazoquinazoline derivatives | |
| AU6206096A (en) | Tie | |
| AU4721897A (en) | Tetrahydroisoquinoline derivatives | |
| AU1735497A (en) | Sulfonylureidopyrazole derivatives | |
| AU3906295A (en) | Pyrrole derivatives | |
| AU2186797A (en) | Pharmaceutically useful compounds | |
| AU7002296A (en) | Analgesic composition | |
| AU3867997A (en) | Chromene-3-carboxylate derivatives | |
| AU2956097A (en) | Alkylaminobenzothiazole and -benzoxazole derivatives | |
| AUPO284396A0 (en) | Benzodiazepine derivatives | |
| EP1008579A3 (fr) | Dérivés de cyclopentanebutanol | |
| HUP9900143A3 (en) | Pharmaceutically useful 3-pyridil-compounds | |
| AU4344696A (en) | Oligonucleotide-dendrimer conjugates | |
| AU2961097A (en) | Substituted pyrazolylpyrazole derivatives | |
| AU4962097A (en) | 2-methoxyphenylpiperazine derivatives | |
| AU1793197A (en) | Pyrazole-4-yl-hetaroyl derivatives | |
| AU5347496A (en) | Ethynylthiazole derivative | |
| AU4296497A (en) | Substituted pyrroles | |
| AU3685097A (en) | N-benzylazolium derivatives | |
| AU3038397A (en) | Neurotransmitters | |
| AU7301296A (en) | Audio-transferred dab | |
| AU4968197A (en) | Novel phenanthridinium derivatives |